語系:
繁體中文
English
說明(常見問題)
登入
回首頁
切換:
標籤
|
MARC模式
|
ISBD
Pharmacokinetics in Drug Development...
~
SpringerLink (Online service)
Pharmacokinetics in Drug Development = Problems and Challenges in Oncology, Volume 4 /
紀錄類型:
書目-語言資料,印刷品 : Monograph/item
正題名/作者:
Pharmacokinetics in Drug Development/ edited by Peter L. Bonate, Danny R. Howard.
其他題名:
Problems and Challenges in Oncology, Volume 4 /
其他作者:
Bonate, Peter L.
面頁冊數:
XII, 330 p. 32 illus., 23 illus. in color.online resource. :
Contained By:
Springer Nature eBook
標題:
Pharmaceutical technology. -
電子資源:
https://doi.org/10.1007/978-3-319-39053-6
ISBN:
9783319390536
Pharmacokinetics in Drug Development = Problems and Challenges in Oncology, Volume 4 /
Pharmacokinetics in Drug Development
Problems and Challenges in Oncology, Volume 4 /[electronic resource] :edited by Peter L. Bonate, Danny R. Howard. - 1st ed. 2016. - XII, 330 p. 32 illus., 23 illus. in color.online resource.
Overview of Oncology Drug Development -- A Global Perspective on First-In-Man Dose Selection: Oncology and Beyond -- Controversies in Oncology: Size-Based vs. Fixed Dosing -- Clinical QTc Assessment in Oncology -- Expediting Drug Development: Breakthrough Therapy Designation -- Pharmacokinetics and Pharmacodynamics of Tyrosine Kinase Inhibitors -- Combination Development -- Role of Pharmacokinetics-Pharmacodynamics in Biosimilar Assessments -- Pharmacokinetics and Pharmacogenetics of Metronomics -- Modeling Tumor Growth in Animals and Humans: an Evolutionary Approach -- Practical Considerations for Clinical Pharmacology in Oncology Drug Development: A Survey of Approvals from 2009-2015 -- New Advancements in Exposure-Response Analysis to Inform Regulatory Decision-Making .
Back cover copy In this volume, the specific challenges and problems facing the evaluation of new oncology agents are explored with regards to pharmacokinetic, pharmacodynamic modeling and clinical pharmacology development strategies. This book delivers, with an emphasis on the oncology therapeutic area, the goals set in the first three volumes: namely – to provide clinical pharmacologists practical insights for the application of pharmacology, pharmacokinetics and pharmacodynamics for new drug development strategies. Pharmacokinetic-pharmacodynamicconcepts for tyrosine kinases,the evaluation of cardiac repolarization prolongation through QTc interval effects, efficacy- and safety-response analyses to support new drug approvals, clinical and preclinical tumor growth modeling, and flat- vs weight-based dose selection are showcased from an oncology clinical pharmacologist’s point-of-view. Oncology development strategies are surveyed for new FDA-approvals to identify patterns in expectations at time of first approval. The special considerations necessary to address combination drug development, metronomics, biosimilars and breakthrough therapies are also presented. .
ISBN: 9783319390536
Standard No.: 10.1007/978-3-319-39053-6doiSubjects--Topical Terms:
557391
Pharmaceutical technology.
LC Class. No.: RS380
Dewey Class. No.: 615.19
Pharmacokinetics in Drug Development = Problems and Challenges in Oncology, Volume 4 /
LDR
:03415nam a22004095i 4500
001
974774
003
DE-He213
005
20200629172636.0
007
cr nn 008mamaa
008
201211s2016 gw | s |||| 0|eng d
020
$a
9783319390536
$9
978-3-319-39053-6
024
7
$a
10.1007/978-3-319-39053-6
$2
doi
035
$a
978-3-319-39053-6
050
4
$a
RS380
050
4
$a
RS190-210
072
7
$a
TDCW
$2
bicssc
072
7
$a
MED072000
$2
bisacsh
072
7
$a
TDC
$2
thema
082
0 4
$a
615.19
$2
23
245
1 0
$a
Pharmacokinetics in Drug Development
$h
[electronic resource] :
$b
Problems and Challenges in Oncology, Volume 4 /
$c
edited by Peter L. Bonate, Danny R. Howard.
250
$a
1st ed. 2016.
264
1
$a
Cham :
$b
Springer International Publishing :
$b
Imprint: Springer,
$c
2016.
300
$a
XII, 330 p. 32 illus., 23 illus. in color.
$b
online resource.
336
$a
text
$b
txt
$2
rdacontent
337
$a
computer
$b
c
$2
rdamedia
338
$a
online resource
$b
cr
$2
rdacarrier
347
$a
text file
$b
PDF
$2
rda
505
0
$a
Overview of Oncology Drug Development -- A Global Perspective on First-In-Man Dose Selection: Oncology and Beyond -- Controversies in Oncology: Size-Based vs. Fixed Dosing -- Clinical QTc Assessment in Oncology -- Expediting Drug Development: Breakthrough Therapy Designation -- Pharmacokinetics and Pharmacodynamics of Tyrosine Kinase Inhibitors -- Combination Development -- Role of Pharmacokinetics-Pharmacodynamics in Biosimilar Assessments -- Pharmacokinetics and Pharmacogenetics of Metronomics -- Modeling Tumor Growth in Animals and Humans: an Evolutionary Approach -- Practical Considerations for Clinical Pharmacology in Oncology Drug Development: A Survey of Approvals from 2009-2015 -- New Advancements in Exposure-Response Analysis to Inform Regulatory Decision-Making .
520
$a
Back cover copy In this volume, the specific challenges and problems facing the evaluation of new oncology agents are explored with regards to pharmacokinetic, pharmacodynamic modeling and clinical pharmacology development strategies. This book delivers, with an emphasis on the oncology therapeutic area, the goals set in the first three volumes: namely – to provide clinical pharmacologists practical insights for the application of pharmacology, pharmacokinetics and pharmacodynamics for new drug development strategies. Pharmacokinetic-pharmacodynamicconcepts for tyrosine kinases,the evaluation of cardiac repolarization prolongation through QTc interval effects, efficacy- and safety-response analyses to support new drug approvals, clinical and preclinical tumor growth modeling, and flat- vs weight-based dose selection are showcased from an oncology clinical pharmacologist’s point-of-view. Oncology development strategies are surveyed for new FDA-approvals to identify patterns in expectations at time of first approval. The special considerations necessary to address combination drug development, metronomics, biosimilars and breakthrough therapies are also presented. .
650
0
$a
Pharmaceutical technology.
$3
557391
650
0
$a
Oncology .
$3
1253469
650
0
$a
Biomathematics.
$3
527725
650
1 4
$a
Pharmaceutical Sciences/Technology.
$3
768561
650
2 4
$a
Oncology.
$3
593951
650
2 4
$a
Mathematical and Computational Biology.
$3
786706
700
1
$a
Bonate, Peter L.
$4
edt
$4
http://id.loc.gov/vocabulary/relators/edt
$3
784514
700
1
$a
Howard, Danny R.
$4
edt
$4
http://id.loc.gov/vocabulary/relators/edt
$3
784515
710
2
$a
SpringerLink (Online service)
$3
593884
773
0
$t
Springer Nature eBook
776
0 8
$i
Printed edition:
$z
9783319390512
776
0 8
$i
Printed edition:
$z
9783319390529
776
0 8
$i
Printed edition:
$z
9783319818054
856
4 0
$u
https://doi.org/10.1007/978-3-319-39053-6
912
$a
ZDB-2-SBL
912
$a
ZDB-2-SXB
950
$a
Biomedical and Life Sciences (SpringerNature-11642)
950
$a
Biomedical and Life Sciences (R0) (SpringerNature-43708)
筆 0 讀者評論
多媒體
評論
新增評論
分享你的心得
Export
取書館別
處理中
...
變更密碼[密碼必須為2種組合(英文和數字)及長度為10碼以上]
登入